BridgeBio announces FDA clearance of IND application for BBO-8520

BBO-8520’s discovery was the result of a collaboration between the RAS Initiative FNL, Lawrence Livermore National Laboratory, and BridgeBio. It is specifically designed to provide patients afflicted with KRAS^G12C mutant cancers with a best-in-class, oral small molecule therapy that directly targets the tumor at its source – oncogenic KRAS^G12C GTP-bound (ON) signaling. Enrollment of patients with KRAS^G12C mutant non-small cell lung cancer into the ONKORAS-101 trial is expected to begin in H1 of this year.